In addition to published data, the benefit of high infiltration in HER2-positive breast cancer and TNBC manifested after two years of observation in our cohort, while in the first few years, other factors seemed to have a more dominant influence on event-free survival. The gene discussed is ERBB2; the disease is breast carcinoma.